Developing Treatment, Treatment Validation, and Treatment Scope in the Setting of an Autism Clinical Trial

Abstract

This project is to test to see if DHA treatment can beneficially affect excretion of urinary biomarkers of oxidative stress and the autism clinical phenotype. In addition polymorphic variants of genes of certain enzymes that synthesize and metabolize docosahexaenoic acid (DHA) may contribute to the phenotype of some autism cases. We will test to see if any of these genes are risk factors for autism. We will also measure changes in excretion of the polyunsaturated fatty acid (PUFA) derived biomarkers of oxidative stress (isoprostanes and neuroprostanes) together with the changes in production of anti-inflammatory lipid mediators. We will test these biomarkers to see if we can monitor and validate effectiveness of DHA therapy. We will also test the genotypes of key DHA-metabolizing enzymes can predict which patients will respond to therapy. Please see partnering projects W81XWH-08-1-0729 and W81XWH-08-1-0730.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2010
Accession Number
ADA540346

Entities

People

  • William G. Johnson

Organizations

  • Robert Wood Johnson Medical School

Tags

DTIC Thesaurus Topics

  • Agreements
  • Biological Markers
  • Biomedical Research
  • Clinical Trials
  • Department Of Defense
  • Excretion
  • Fatty Acids
  • Genes
  • Genetics
  • Genotypes
  • Intellectual Property
  • Materials
  • Monitoring
  • Oxidative Stress
  • Phenotypes
  • Tissue Banks
  • Validation

Fields of Study

  • Medicine

Readers

  • Clinical Trial Research.
  • Prostate Cancer Biology.